Gilead announces plans to study remdesivir in paediatric patients with COVID-19

The planned single-arm Phase II/III clinical trial of remdesivir will enrol around 50 paediatric patients (newborns through to adolescents) with moderate-to-severe COVID-19, and will involve over 30 locations in the U.S. and Europe.

Source:

Biospace Inc.